Capricor Therapeutics (CAPR) Misses Q4 EPS by 2c

Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen